Loading...
Loading...
In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on
HospiraHSP.
In the report, Morgan Stanley noted, “Potential acquisition of Danone's medical nutritional business may provide strategic flexibility but lower tax rates and access to OUS cash via inversion is the likely driver. Our first look has ~20% accretion, more modest than some inversion deals of late and returns of 7%, likely below HSP's WACC.”
Hospira closed on Friday at $51.72.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in